In this cross-sectional analysis of a prospective COVID-19 recovery cohort, we found that higher antibody levels, markers of inflammation (hsCRP and possibly IL-6), and possibly pericardial effusions were associated with cardiopulmonary PASC at a median of 7 months after infection with SARS-CoV-2. The gene discussed is IL6; the disease is COVID-19.